嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展

刘奕晨; 孙志强; 郑方

文章摘要

刘奕晨,孙志强,郑方.嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展[J].安徽医药,2017,21(6):978-982.

嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展

The review of application and challenge of CAR-T in the treatment of multiple myelomaLIU Yichen¹,SUN Zhiqiang^2,3,ZHEN Fang^2,4 (1.Graduate School,Guizhou Medical University,Guiyang,Guizhou 550000,China；2.Department of Hematology, The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550000,China；3.Department of Hematology, Shenzhen Hospital Affiliated to Southern Medical University,Shenzhen,Guangdong 518000,China；4.Department of Hematology,Baiyun Hospital Affiliated to Guizhou Medical University,Guiyang,Guizhou 550000,China) Abstract:

投稿时间：2016-08-10

DOI：

中文关键词: 嵌合抗原受体多发性骨髓瘤免疫治疗

英文关键词:

基金项目:

作者	单位
刘奕晨	贵州医科大学研究生院,贵州贵阳 550000
孙志强	贵州医科大学附属医院血液内科, 贵州贵阳 550000 南方医科大学深圳医院血液内科,广东深圳 518000
郑方	贵州医科大学附属医院血液内科, 贵州贵阳 550000 贵州医科大学附属白云医院血液内科,贵州贵阳 550000

摘要点击次数: 6942

全文下载次数: 1240

中文摘要:

免疫疗法在恶性肿瘤治疗中的应用正日益受到关注。嵌合抗原受体(CAR)技术是一种新兴的免疫疗法,在血液肿瘤的治疗上具有巨大的潜力。嵌合抗原受体T细胞免疫疗法(CAR-T)可通过特异性识别靶抗原来杀伤骨髓瘤细胞,使治疗复发难治性多发性骨髓瘤成为可能。该文重点对CAR-T在多发性骨髓瘤治疗方面的研究进展作一综述,并对可能作为CAR-T治疗多发性骨髓瘤的靶抗原进行了分析。

英文摘要:

Application of immunotherapy in malignant tumor has widely been focused.Chimeric antigen receptor is one of the emerging immunotherapy and has enormous potentiality to treat hematologic neoplasms.Chimeric antigen receptor-modified Tcells(CAR-T) may contribute to treat multiple myeloma as CAR-T can kill target myeloma cells by means of identifying the target antigen.In this article,the research advances of CAR-T in treating multiple myeloma were reviewed,and the antigens which may be an effective target for CAR-T in eliminating myeloma cells were analyzed.

查看全文查看/发表评论下载PDF阅读器

关闭